TVTX

Sparsentan

IgA nephropathy (IgAN)

Phase 3 (Top-line Data)

Exp Date

Q3 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Sparsentan in the Treatment of Patients With IgA Nephropathy 

  • ClinicalTrial.gov (NCT03762850): A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)


WHAT IS THE CATALYST EVENT?

  • Phase 3 Top-line Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA/EVENTS

PRESS RELEASE

MECHANISM OF ACTION

  • Sparsentan is an investigational product candidate in Phase 3 clinical development that has a dual mechanism of action combining endothelin receptor type A blockade with angiotensin receptor blockade. Retrophin is developing sparsentan for the treatment of IgAN, as well as for focal segmental glomerulosclerosis (FSGS), rare kidney disorders that often lead to ESRD. In several forms of chronic kidney disease, such as IgAN and FSGS, endothelin receptor blockade has been shown to have an additive beneficial effect on proteinuria in combination with renin-angiotensin blockade via angiotensin receptor blockade or angiotensin converting enzyme inhibitors. Sparsentan has been granted orphan drug designation for the treatment of FSGS by the FDA and European Commission.

MARKET

  • IgAN frequently occurs in adolescence or early adulthood, usually in the second and third decades of life.

  • Estimated incidence of IgAN is 2.5 per 100,000 individuals per year among adults, with geographic, racial and ethnic variations in prevalence.

  • Prevalence of IgAN may be higher in individuals of Pacific Asian and southern European descent versus those of North American and northern European descent.

  • In the US, IgAN is the most common primary glomerular disease in young Caucasian adults.

Updated by HC

TVTX, IgA nephropathy (IgAN), Berger's disease, kidney disease immunoglobulin A (IgA), inflammation, Sparsentan

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon